Jane Street Group LLC Sells 37,349 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Jane Street Group LLC trimmed its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 61.9% during the third quarter, HoldingsChannel reports. The fund owned 23,002 shares of the medical instruments supplier’s stock after selling 37,349 shares during the quarter. Jane Street Group LLC’s holdings in Harvard Bioscience were worth $62,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of HBIO. State Street Corp increased its position in shares of Harvard Bioscience by 1.1% during the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock worth $1,930,000 after buying an additional 7,763 shares during the period. Harvey Partners LLC boosted its position in shares of Harvard Bioscience by 6.2% during the third quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock valued at $7,303,000 after buying an additional 157,500 shares during the last quarter. Corsair Capital Management L.P. bought a new stake in shares of Harvard Bioscience in the 3rd quarter worth $63,000. Advantage Alpha Capital Partners LP bought a new position in shares of Harvard Bioscience during the 3rd quarter worth approximately $64,000. Finally, Landscape Capital Management L.L.C. purchased a new position in Harvard Bioscience in the third quarter worth $50,000. 80.87% of the stock is currently owned by institutional investors and hedge funds.

Harvard Bioscience Stock Performance

NASDAQ HBIO opened at $1.98 on Thursday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06. The company has a market capitalization of $86.36 million, a PE ratio of -6.00 and a beta of 1.27. The company has a 50-day simple moving average of $2.19 and a 200 day simple moving average of $2.58. Harvard Bioscience, Inc. has a 52-week low of $1.80 and a 52-week high of $4.93.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.